Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 6/20 | 0.52 |
| ▸ | MMP9 | P14780 | 6/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.48 |
| ▸ | GLS | O94925 | 1/20 | 0.47 |
| ▸ | MMP3 | P08254 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6579291 | 1.00 | MMP2 (0.52) | MMP2MMP9CA12CA9ALDH1A1 | |
| SCHEMBL6577298 | 0.87 | ALDH1A1 (0.50) | MMP2MMP9CA12CA9ALDH1A1 | |
| SCHEMBL6577303 | 0.87 | ALDH1A1 (0.50) | MMP2MMP9CA12CA9ALDH1A1 | |
| SCHEMBL7080833 | 0.84 | ALDH1A1 (0.58) | MMP2MMP9CA12CA9ALDH1A1 | |
| SCHEMBL1286243 | 0.81 | ALDH1A1 (0.55) | MMP2MMP9CA12CA9ALDH1A1 | |
| SCHEMBL1781793 | 0.81 | ALDH1A1 (0.55) | MMP2MMP9CA12CA9ALDH1A1 | |
| SCHEMBL7079889 | 0.81 | MMP2 (0.49) | MMP2MMP9CA12CA9ALDH1A1 | |
| SCHEMBL7026832 | 0.81 | HDAC1 (0.52) | MMP2MMP9CA12CA9ALDH1A1 | |
| SCHEMBL7286787 | 0.80 | CA12 (0.51) | MMP2MMP9CA12CA9ALDH1A1 | |
| SCHEMBL876560 | 0.80 | SMN1; SMN2 (0.53) | MMP2MMP9CA12CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040171849-A1 | Process for producing optically active azetidine-2-carboxylic acid | KANEKA CORPORATION (JP) | 2004-09-02 | — | — | US | disclosed |
| EP-1415985-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE AZETIDINE-2-CARBOXYLIC ACID | KANEKA CORPORATION (JP) | 2004-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171849-A1 | Process for producing optically active azetidine-2-carboxylic acid | HBB, ADCY2, ADCY9 | MMP2 1999/4885MMP9 1079/4885CA12 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.